Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

By A. Barrett, Zachary T Britton, Rosa A Carrasco, S. Breen, Maria A S Broggi, Amy Hatke, Benjamin Clark, Chunning Yang, Sandrina Phipps, L. Ortiz and 13 more. 2024

Subfields: Cancer Research, Immunology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “2 positivity (3/54 tumors) precludes meaningful clinical interpretation, despite its role in gastrointestinal cancer therapeutics [32, 33].”